Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8877887 | 0.99 | PARP15 (0.43) | PARP15PARP10KCNH2PTPN1AR | |
| SCHEMBL8877885 | 0.99 | PARP15 (0.43) | PARP15PARP10KCNH2PTPN1AR | |
| SCHEMBL7634857 | 0.88 | AR (0.37) | ARMAOB | |
| SCHEMBL7631011 | 0.84 | GABRG2 (0.34) | MAOB | |
| SCHEMBL10281143 | 0.81 | PTPN1 (0.48) | PARP15PARP10PTPN1MAOBPTPN2 | |
| SCHEMBL8876338 | 0.81 | PRKDC (0.41) | PARP10PTPN1MCHR1NPC1RAB9A | |
| SCHEMBL7637096 | 0.80 | NR4A2 (0.42) | PTPN1MCHR1 | |
| SCHEMBL7634109 | 0.80 | KMT2A (0.38) | ARMAOBSMN1; SMN2 | |
| SCHEMBL7635956 | 0.79 | PTPN1 (0.45) | PARP15PARP10KCNH2PTPN1AR | |
| SCHEMBL8824985 | 0.77 | ACHE (0.39) | MAOBOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5594016-A | ANTIDIABETIC AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-01-14 | — | — | US | claimed |
| WO-2009043593-A1 | COMBINATION THERAPY USING MEMANTINE AND GLITAZONES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-04-09 | — | — | WO | disclosed |
| US-20040198774-A1 | Preventive and/or remedial agent for disease attributable to arteriosclerotic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1419771-A1 | PREVENTIVE AND/OR REMEDIAL AGENT FOR DISEASE ATTRIBUTABLE TO ARTERIOSCLEROTIC ACTIVITY | Mitsubishi Pharma Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| EP-1186588-A1 | 6-HYDROXY-2-NAPHTHYLCARBINOL AND PROCESS FOR THE PREPARATION THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-5594016-A | ANTIDIABETIC AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0604983-B1 | Naphthalene derivatives | MITSUBISHI CHEM CORP (JP) | 1996-11-20 | — | — | EP | disclosed |
| EP-0604983-A1 | Naphthalene derivatives | Mitsubishi Chemical Corporation (JP) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198774-A1 | Preventive and/or remedial agent for disease attributable to arteriosclerotic activity | NR1H2, MSR1, APOB | PARP15 4076/4885PARP10 4324/4885KCNH2 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.